MedTrace Logo

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

NCT02654639 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-08-07

Study results available
· View outcomes & findings →

Summary

Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC

Conditions

Interventions

DRUG

TAS-102

TAS-102 Twice a day by mouth day 1-5 and 8-12

DRUG

Bevacizumab

Bevacizumab by intravenous infusion once every 14 days

Sponsors & Collaborators

  • Georgetown University

    lead OTHER

Principal Investigators

  • Mohamed Salem, MD · Georgetown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02654639 on ClinicalTrials.gov